140 related articles for article (PubMed ID: 36476191)
1. Disruption of GCN2 Pathway Aggravates Vascular and Parenchymal Remodeling during Pulmonary Fibrosis.
Santos-Ribeiro D; Lecocq M; de Beukelaer M; Verleden S; Bouzin C; Ambroise J; Dorfmuller P; Yakoub Y; Huaux F; Quarck R; Karmouty-Quintana H; Ghigna MR; Bignard J; Nadaud S; Soubrier F; Horman S; Perros F; Godinas L; Pilette C
Am J Respir Cell Mol Biol; 2023 Mar; 68(3):326-338. PubMed ID: 36476191
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease.
Nossent EJ; Antigny F; Montani D; Bogaard HJ; Ghigna MR; Lambert M; Thomas de Montpréville V; Girerd B; Jaïs X; Savale L; Mercier O; Fadel E; Soubrier F; Sitbon O; Simonneau G; Vonk Noordegraaf A; Humbert M; Perros F; Dorfmüller P
J Heart Lung Transplant; 2018 May; 37(5):647-655. PubMed ID: 29108819
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment with fasudil improves bleomycin-induced pulmonary fibrosis and pulmonary hypertension via inhibition of Smad2/3 phosphorylation.
Bei Y; Hua-Huy T; Duong-Quy S; Nguyen VH; Chen W; Nicco C; Batteux F; Dinh-Xuan AT
Pulm Pharmacol Ther; 2013 Dec; 26(6):635-43. PubMed ID: 23928001
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Human and Experimental Pulmonary Veno-Occlusive Disease.
Manaud G; Nossent EJ; Lambert M; Ghigna MR; Boët A; Vinhas MC; Ranchoux B; Dumas SJ; Courboulin A; Girerd B; Soubrier F; Bignard J; Claude O; Lecerf F; Hautefort A; Florio M; Sun B; Nadaud S; Verleden SE; Remy S; Anegon I; Bogaard HJ; Mercier O; Fadel E; Simonneau G; Vonk Noordegraaf A; Grünberg K; Humbert M; Montani D; Dorfmüller P; Antigny F; Perros F
Am J Respir Cell Mol Biol; 2020 Jul; 63(1):118-131. PubMed ID: 32209028
[TBL] [Abstract][Full Text] [Related]
5. Loss of the eukaryotic initiation factor 2α kinase general control nonderepressible 2 protects mice from pressure overload-induced congestive heart failure without affecting ventricular hypertrophy.
Lu Z; Xu X; Fassett J; Kwak D; Liu X; Hu X; Wang H; Guo H; Xu D; Yan S; McFalls EO; Lu F; Bache RJ; Chen Y
Hypertension; 2014 Jan; 63(1):128-35. PubMed ID: 24166753
[TBL] [Abstract][Full Text] [Related]
6. 2-methoxyestradiol attenuates bleomycin-induced pulmonary hypertension and fibrosis in estrogen-deficient rats.
Tofovic SP; Zhang X; Jackson EK; Zhu H; Petrusevska G
Vascul Pharmacol; 2009; 51(2-3):190-7. PubMed ID: 19540933
[TBL] [Abstract][Full Text] [Related]
7. Improvement of bleomycin-induced pulmonary hypertension and pulmonary fibrosis by the endothelin receptor antagonist Bosentan.
Schroll S; Arzt M; Sebah D; Nüchterlein M; Blumberg F; Pfeifer M
Respir Physiol Neurobiol; 2010 Jan; 170(1):32-6. PubMed ID: 19931426
[TBL] [Abstract][Full Text] [Related]
8. The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension.
Shenoy V; Ferreira AJ; Qi Y; Fraga-Silva RA; Díez-Freire C; Dooies A; Jun JY; Sriramula S; Mariappan N; Pourang D; Venugopal CS; Francis J; Reudelhuber T; Santos RA; Patel JM; Raizada MK; Katovich MJ
Am J Respir Crit Care Med; 2010 Oct; 182(8):1065-72. PubMed ID: 20581171
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of adipose stem cell-derived conditioned medium against pulmonary hypertension and lung fibrosis.
Rathinasabapathy A; Bruce E; Espejo A; Horowitz A; Sudhan DR; Nair A; Guzzo D; Francis J; Raizada MK; Shenoy V; Katovich MJ
Br J Pharmacol; 2016 Oct; 173(19):2859-79. PubMed ID: 27448286
[TBL] [Abstract][Full Text] [Related]
10. GCN2 Regulates ATF3-p38 MAPK Signaling Transduction in Pulmonary Veno-Occlusive Disease.
Chen Z; Zhang J; Wei D; Chen J; Yang J
J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):677-689. PubMed ID: 33988041
[TBL] [Abstract][Full Text] [Related]
11. Unique wreath-like smooth muscle proliferation of the pulmonary vasculature in pulmonary veno-occlusive disease versus pulmonary arterial hypertension.
Lai YJ; Chen PR; Huang YL; Hsu HH
J Formos Med Assoc; 2020 Jan; 119(1 Pt 2):300-309. PubMed ID: 31202500
[TBL] [Abstract][Full Text] [Related]
12. Fluorofenidone attenuates bleomycin-induced pulmonary fibrosis by inhibiting eukaryotic translation initiation factor 3a (eIF3a) in rats.
Wu YH; Li XW; Li WQ; Li XH; Li YJ; Hu GY; Liu ZQ; Li D
Eur J Pharmacol; 2016 Feb; 773():42-50. PubMed ID: 26821114
[TBL] [Abstract][Full Text] [Related]
13. SPECT imaging of pulmonary vascular disease in bleomycin-induced lung fibrosis using a vascular endothelium tracer.
Harel F; Nguyen QT; Nsaibia MJ; Finnerty V; Morgan A; Sirois M; Villeneuve L; Calderone A; Bergeron A; Brochiero E; Tardif JC; Shi Y; Dupuis J
Respir Res; 2021 Sep; 22(1):240. PubMed ID: 34481508
[TBL] [Abstract][Full Text] [Related]
14. T-cell dysregulation and inflammatory process in
Bignard J; Atassi F; Claude O; Ghigna MR; Mougenot N; Abdoulkarim BS; Deknuydt F; Gestin A; Monceau V; Montani D; Nadaud S; Soubrier F; Perros F
Am J Physiol Lung Cell Mol Physiol; 2023 May; 324(5):L609-L624. PubMed ID: 36852942
[TBL] [Abstract][Full Text] [Related]
15. Preventive Effects of Rhodiola rosea L. on Bleomycin-Induced Pulmonary Fibrosis in Rats.
Zhang K; Si XP; Huang J; Han J; Liang X; Xu XB; Wang YT; Li GY; Wang HY; Wang JH
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27271612
[TBL] [Abstract][Full Text] [Related]
16. Protective Effect of Ginsenoside Rg1 on Bleomycin-Induced Pulmonary Fibrosis in Rats: Involvement of Caveolin-1 and TGF-β1 Signal Pathway.
Zhan H; Huang F; Ma W; Zhao Z; Zhang H; Zhang C
Biol Pharm Bull; 2016; 39(8):1284-92. PubMed ID: 27476938
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of caveolin-1 during pathogenesis of combined pulmonary fibrosis and emphysema: Effect of phosphodiesterase-5 inhibitor.
Kulshrestha R; Singh H; Pandey A; Soundarya D; Jaggi AS; Ravi K
Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165802. PubMed ID: 32311453
[TBL] [Abstract][Full Text] [Related]
18. Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis.
Bruce E; Shenoy V; Rathinasabapathy A; Espejo A; Horowitz A; Oswalt A; Francis J; Nair A; Unger T; Raizada MK; Steckelings UM; Sumners C; Katovich MJ
Br J Pharmacol; 2015 May; 172(9):2219-31. PubMed ID: 25522140
[TBL] [Abstract][Full Text] [Related]
19. Bleomycin-induced lung injury: Revisiting an old tool to model group III PH associated with pulmonary fibrosis.
Santos-Ribeiro D; Lecocq M; de Beukelaer M; Bouzin C; Palmai-Pallag M; Yakoub Y; Huaux F; Horman S; Perros F; Pilette C; Godinas L
Pulm Circ; 2023 Jan; 13(1):e12177. PubMed ID: 36618712
[TBL] [Abstract][Full Text] [Related]
20. Exercise Preconditioning Protects against Acute Cardiac Injury Induced by Lipopolysaccharide Through General Control Nonderepressible 2 Kinase.
Sun ZG; Lu G; Zhao LL; Zhang LZ; Li A; Jing J; Xu X
Int Heart J; 2020 Jan; 61(1):138-144. PubMed ID: 31875620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
